AVEO Pharmaceuticals - AVEO Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AVEO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVEO, but not buy additional shares or sell existing shares.
View AVEO analyst ratings or view top-rated stocks.

5 analysts have issued 1 year price targets for AVEO Pharmaceuticals' stock. Their AVEO share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next year.
View analysts price targets for AVEO or view top-rated stocks among Wall Street analysts.

AVEO Pharmaceuticals' stock was trading at $14.95 at the start of the year. Since then, AVEO stock has increased by 0.3% and is now trading at $15.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our AVEO earnings forecast.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to analyst estimates of $14.29 million. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 81.66% and a negative net margin of 30.79%. During the same period in the previous year, the company earned ($0.33) earnings per share.

AVEO Pharmaceuticals shares reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

AVEO Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Trium Capital LLP (0.35%), Birchview Capital LP (0.29%), Wolverine Asset Management LLC (0.06%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Michael Ferraresso, Michael P Bailey and Peter W Sonsini.
View institutional ownership trends.

Shares of AVEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVEO stock can currently be purchased for approximately $15.00.

AVEO Pharmaceuticals (NASDAQ:AVEO) has a market capitalization of $521.45 million and generates $42.29 million in revenue each year. The biopharmaceutical company earns $-53,340,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

The company employs 114 workers across the globe.

AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The official website for the company is www.aveooncology.com. The biopharmaceutical company can be reached via phone at (617) 400-0101, via email at ir@aveooncology.com, or via fax at 617-995-4995.